BioJAMP

Making the Complex Simple

BioJAMP provides value-added biosimilar products that meet the needs of patients and healthcare professionals. We are committed to simplifying collaboration for healthcare professionals and their patients without compromising the efficacy, quality or safety of the products we offer.

Our mission is to provide biosimilar products that meet the needs of patients and healthcare professionals.

Products ^{8 products coming soon}

Discover your Patient Support Program ^{JAMP Care ^TM}

JAMP Pharma Group launches PrPexegra® (pegfilgrastim) and PrFilra® (filgrastim), two new biosimilar therapeutic options in oncology

JAMP Pharma Group launches PrPexegra®, a biosimilar alternative to the reference product PrNeulasta® (commercialized in Canada by Amgen Canada Inc.). JAMP Pharma Group also launches PrFilra®, a biosimilar alternative to the reference product PrNeupogen® (commercialized in Canada by Amgen Canada Inc.). JAMP Pharma Group, through its BioJAMP® division, is strengthening…
September 25, 2025
BIOJAMP, Press release
Alvotech and JAMP Pharma announce receipt of marketing authorization for PrJamtekiTM (AVT04), the first biosimilar of Stelara® (ustekinumab)

PrJamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. REYKJAVIK, ICELAND & BOUCHERVILLE, QC (November 9, 2023) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group (“JAMP…
November 14, 2023
BIOJAMP, New launches, News and events, Press release
BIOJAMP: A Range of Biosimilars for a Seamless Approach

BIOJAMPTM, a division within the JAMP Pharma Group, is dedicated to improving and simplifying the complex world of biosimilars for patients and healthcare professionals. BIOJAMPTM and its JAMP CareTM patient support program offer a seamless experience for patients and healthcare professionals. BIOJAMPTM also aims to promote a range of products…
February 1, 2022
Press release

Other divisions ⁷

JAMP Pharma
BIOJAMP
Orimed
Laboratoire Suisse
Cosmetic Import
Wampole
JAMP Pharma Manufacturing

BioJAMP

Making the Complex Simple

Our mission is to provide biosimilar products that meet the needs of patients and healthcare professionals.

JAMP Pharma Group launches PrPexegra® (pegfilgrastim) and PrFilra® (filgrastim), two new biosimilar therapeutic options in oncology

Alvotech and JAMP Pharma announce receipt of marketing authorization for PrJamtekiTM (AVT04), the first biosimilar of Stelara® (ustekinumab)

BIOJAMP: A Range of Biosimilars for a Seamless Approach

JAMP Pharma

BIOJAMP

Orimed

Laboratoire Suisse

Cosmetic Import

Wampole

JAMP Pharma Manufacturing